What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Notch Delta Signaling: Mechanisms, Methods, and Misconceptions

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Notch Delta Signaling

Notch Delta signaling is a highly conserved juxtacrine cell–cell communication pathway in which a membrane-bound Delta ligand on one cell activates a membrane-bound Notch receptor on an adjacent cell. Unlike secreted signaling molecules such as Wnt or Hedgehog, Notch Delta signaling requires direct physical contact between the two participating cells. This proximity-based mechanism allows the pathway to make precise, local cell fate decisions during development and adult tissue homeostasis.

Historical Discovery

The Notch gene was first identified in 1917 by Thomas Hunt Morgan's laboratory in Drosophila melanogaster, where a partial loss-of-function allele produced notches in the wing margin. The name "Notch" derives from this visible wing phenotype. Decades later, in the 1980s and 1990s, molecular cloning revealed that Notch encodes a large single-pass transmembrane receptor. The Delta ligand was identified through genetic screens for mutations that produced similar neurogenic phenotypes—embryos in which neural progenitors failed to differentiate, leading to hypertrophy of the nervous system at the expense of epidermis. These early genetic studies established that Notch and Delta function in the same signaling pathway and that the interaction is essential for lateral inhibition during neurogenesis.

Core Components: Notch Receptor and Delta Ligand

The Notch receptor is a type I transmembrane protein. In mammals, four paralogs exist: NOTCH1, NOTCH2, NOTCH3, and NOTCH4. The mature receptor is a heterodimer held together by non-covalent calcium-dependent interactions. The extracellular domain contains 29–36 tandem epidermal growth factor (EGF)-like repeats, of which EGF repeats 11–12 are required for ligand binding. The intracellular domain contains a RAM domain, seven ankyrin (ANK) repeats, a transactivation domain, and a PEST sequence that regulates protein stability.

Delta ligands—encoded by DLL1, DLL3, and DLL4 in mammals, and by Serrate/Jagged genes (JAG1, JAG2) in the Jagged family—are also type I transmembrane proteins. Their extracellular region contains an N-terminal MNNL domain, a Delta/Serrate/Lag-2 (DSL) domain essential for receptor binding, and multiple EGF-like repeats. The DSL domain is the minimal motif required for Notch activation.

A critical feature of both receptor and ligand is that they are synthesized as single polypeptide chains and cleaved during maturation. Notch is cleaved by a furin-like convertase at the S1 site in the trans-Golgi network, producing the extracellular and transmembrane subunits that assemble into the mature heterodimer. Delta ligands are also cleaved, though the functional significance of ligand processing is less well understood.

The Core Mechanism of Notch Activation

Notch activation is a multi-step process that converts a membrane-tethered receptor into a nuclear transcriptional regulator. The pathway has no enzymatic amplification step—no kinase cascade, no second messengers. Instead, signal transduction relies entirely on regulated proteolysis.

Ligand–Receptor Interaction

The initiating event is the binding of a Delta ligand on the signal-sending cell to the Notch receptor on the signal-receiving cell. This interaction occurs between EGF repeats 11–12 of Notch and the DSL domain of Delta. The binding affinity is moderate (Kd in the low micromolar range), which is appropriate for a transient cell–cell interaction.

For ligand binding to result in receptor activation, the ligand must be presented in a signaling-competent form. This requires the ligand to be internalized and then recycled back to the plasma membrane in a process called "recycling-dependent signaling." The endocytic proteins Dynamin and Epsin are required in the signal-sending cell for ligand activation. Mutations that block ligand endocytosis abolish signaling, demonstrating that simple receptor–ligand binding is insufficient.

Upon ligand binding, the Notch extracellular domain undergoes a conformational change that exposes a previously buried cleavage site. This site, termed S2, is located just outside the transmembrane domain and is normally protected by the negative regulatory region (NRR), a three-part domain composed of three Lin12-Notch repeats and a heterodimerization domain. The conformational change induced by ligand binding opens the NRR, making the S2 site accessible.

Proteolytic Cleavage Steps (S2, S3)

The proteolytic cascade proceeds in a strict order:

S2 cleavage: The metalloprotease ADAM17 (TACE) or ADAM10 cleaves Notch at the S2 site, releasing the extracellular domain. The released extracellular fragment is trans-endocytosed into the signal-sending cell along with the ligand, a process that provides additional mechanical force to further destabilize the receptor.

S3 cleavage: The membrane-tethered intermediate, called NEXT (Notch extracellular truncation), becomes a substrate for the γ-secretase complex. This intramembrane protease complex, composed of Presenilin 1 or 2, Nicastrin, APH-1, and PEN-2, cleaves within the transmembrane domain at the S3 site. This cleavage releases the Notch intracellular domain (NICD) from the membrane.

S4 cleavage: A secondary γ-secretase cleavage occurs near the membrane-cytoplasm interface, releasing a short peptide and generating the final, stable NICD species.

The γ-secretase cleavage is unusual because it occurs within the hydrophobic environment of the lipid bilayer. The enzyme complex recognizes the transmembrane domain of NEXT and cleaves it at a site approximately three amino acids into the cytoplasmic leaflet. This cleavage is the target of γ-secretase inhibitors, which are used experimentally and have been explored therapeutically.

NICD Nuclear Translocation

Once released, NICD translocates to the nucleus via a nuclear localization sequence located in the RAM domain. In the nucleus, NICD binds to the transcription factor CSL (CBF1/RBP-Jκ in mammals, Suppressor of Hairless in Drosophila, Lag-1 in C. elegans; collectively abbreviated as CSL). In the absence of NICD, CSL associates with co-repressor proteins such as SMRT/NCoR and histone deacetylases, maintaining target genes in a repressed state.

NICD binding displaces the co-repressor complex and recruits co-activators, including Mastermind-like (MAML) proteins and the histone acetyltransferase p300. The resulting ternary complex—NICD–CSL–MAML—activates transcription of Notch target genes. The primary direct targets include the HES (Hairy/Enhancer of Split) family of basic helix-loop-helix transcription factors, as well as HEY genes, MYC, CCND1 (cyclin D1), and DTX1 (Deltex). HES proteins then repress expression of proneural genes such as ASCL1 (Mash1), thereby preventing neuronal differentiation.

NICD is short-lived in the nucleus. The PEST domain at its C-terminus is phosphorylated by CDK8 and casein kinase II, which creates a binding site for the E3 ubiquitin ligase FBXW7 (Sel10). Ubiquitination targets NICD for proteasomal degradation, ensuring that signaling is transient and tightly controlled. The half-life of NICD is typically 20–60 minutes, depending on the cell type.

Regulation of Notch Delta Signaling

The Notch pathway is subject to multiple layers of regulation at the level of ligand expression, receptor modification, endocytic trafficking, and intracellular degradation. These regulatory mechanisms allow the pathway to generate diverse outcomes from a relatively simple signaling cassette.

Glycosylation by Fringe

The EGF repeats of the Notch receptor are modified by O-linked glycosylation, and this modification modulates ligand sensitivity. The enzyme Fringe (encoded by LFNG, MFNG, and RFNG in mammals) adds N-acetylglucosamine to O-fucose residues on specific EGF repeats. This modification enhances signaling by Delta ligands but inhibits signaling by Jagged/Serrate ligands.

The mechanism is structural: Fringe-mediated glycosylation alters the conformation of EGF repeats 8–12, changing the binding interface. Delta ligands bind more efficiently to glycosylated Notch, while Jagged ligands bind less efficiently. This differential regulation is particularly important in the Drosophila wing margin, where Fringe expression in the dorsal compartment creates a boundary of differential Notch activation that patterns the wing.

In mammals, Lunatic Fringe (LFNG) is essential for somitogenesis. Loss of LFNG in mice results in severe somite defects, demonstrating that precise regulation of Notch sensitivity is required for the segmentation clock.

Endocytosis and Trafficking

Endocytosis regulates Notch signaling in both the signal-sending and signal-receiving cells. In the signal-sending cell, ligand endocytosis is required for signaling competence. The current model proposes that endocytosis generates a "pulling force" on the ligand–receptor complex, which mechanically unfolds the Notch NRR and exposes the S2 cleavage site. This model is supported by experiments showing that tethering the ligand to a rigid substrate, preventing endocytosis, abolishes signaling.

In the signal-receiving cell, endocytosis of the Notch receptor can either promote or inhibit signaling depending on the context. Clathrin-mediated endocytosis of the full-length receptor can target it for degradation, reducing signaling. However, some studies suggest that receptor endocytosis into signaling endosomes may be required for efficient γ-secretase cleavage. The precise role of receptor endocytosis remains an area of active investigation.

Ubiquitination by the E3 ligases Itch and Nedd4 targets the Notch receptor for lysosomal degradation, providing a mechanism to limit signaling. Conversely, the deubiquitinase USP10 can remove ubiquitin and stabilize the receptor.

Negative Regulators

Several proteins negatively regulate Notch signaling at different levels:

Numb: An endocytic adaptor protein that promotes Notch receptor endocytosis and degradation. Numb is asymmetrically segregated during asymmetric cell division in Drosophila neuroblasts, ensuring that only one daughter cell receives Notch signaling. This asymmetry is a classic example of how cell polarity controls signaling outcomes.

NICD degradation: As described above, FBXW7-mediated ubiquitination targets NICD for proteasomal degradation. Loss-of-function mutations in FBXW7 are found in T-cell acute lymphoblastic leukemia (T-ALL), leading to sustained Notch signaling.

Lunatic Fringe: Beyond its glycosyltransferase activity, LFNG also acts as a negative feedback regulator. Notch signaling induces LFNG expression, and the resulting Fringe protein modifies Notch receptors, altering their ligand sensitivity. This feedback loop is central to the oscillatory expression of LFNG during somitogenesis.

NICD-interacting proteins: Proteins such as Deltex can promote non-canonical Notch signaling or target the receptor for degradation, depending on context.

Cellular Outcomes and Developmental Roles

Notch Delta signaling produces distinct cellular outcomes depending on the cellular context and the dose and duration of signaling. The pathway is remarkably pleiotropic, influencing proliferation, differentiation, apoptosis, and cell survival.

Lateral Inhibition

Lateral inhibition is the best-characterized outcome of Notch Delta signaling. In this process, a cell that adopts a particular fate expresses Delta, which activates Notch in neighboring cells. Notch activation in those neighbors represses their expression of Delta and of proneural genes, preventing them from adopting the same fate. The result is a "salt-and-pepper" pattern of differentiated cells surrounded by undifferentiated cells.

The classic example is Drosophila neurogenesis. In the neuroectoderm, cells expressing the proneural genes achaete-scute begin to express Delta. Delta activates Notch in adjacent cells, which then express HES genes that repress proneural gene expression. The cell with the highest Delta expression becomes a neuroblast, while its neighbors become epidermal cells. This mechanism is also operative in mammalian neurogenesis, where it controls the timing and spacing of neuronal differentiation. For a detailed discussion, see Notch Signaling and Neuronal Development and Notch Signaling in Neurogenesis.

Boundary Formation

Notch Delta signaling also establishes boundaries between groups of cells with different developmental fates. In the Drosophila wing imaginal disc, the boundary between the dorsal and ventral compartments is established by the interaction between Fringe and Notch. Dorsal cells express Fringe, which modifies Notch such that it responds preferentially to Delta. Ventral cells express Delta, while dorsal cells express Serrate. At the boundary, cells on both sides receive Notch signals, but the signal is strongest at the interface, leading to expression of the transcription factor Vestigial and formation of the wing margin.

In vertebrates, Notch signaling establishes the boundary between the inner cell mass and trophectoderm in the early embryo, and between the neural plate and epidermis. The Vegf Notch Signaling axis is critical for establishing arterial-venous boundaries during vascular development, where Notch signaling in endothelial cells specifies arterial identity.

Stem Cell Maintenance

Notch signaling maintains stem cell populations in multiple tissues by preventing differentiation. In the intestinal crypt, Notch activation in intestinal stem cells maintains their proliferative, undifferentiated state. When Notch signaling is blocked, these cells differentiate into secretory cells (goblet cells, enteroendocrine cells) at the expense of absorptive enterocytes. Similarly, in the hematopoietic system, Notch signaling is required for the maintenance of hematopoietic stem cells, though its role is context-dependent and stage-specific.

In the nervous system, Notch signaling maintains neural stem cells (radial glial cells) in the ventricular zone. During neurogenesis, Notch activity is high in progenitors and decreases as cells commit to neuronal differentiation. The interplay between Notch and other pathways, such as Wnt Signaling Pathway, coordinates stem cell maintenance with proliferation.

Notch Delta Signaling in Disease

Given its central role in development and tissue homeostasis, it is not surprising that dysregulated Notch Delta signaling contributes to numerous human diseases.

Oncogenic Mutations

The most direct link between Notch signaling and cancer comes from T-cell acute lymphoblastic leukemia (T-ALL). Approximately 50–60% of human T-ALL cases harbor activating mutations in NOTCH1. These mutations fall into two classes:

Mutations in the heterodimerization domain: These destabilize the interaction between the extracellular and transmembrane subunits, making the receptor susceptible to ligand-independent S2 cleavage.

Mutations in the PEST domain: These truncate the PEST sequence, preventing FBXW7-mediated ubiquitination and degradation, thereby prolonging NICD half-life.

Both classes result in ligand-independent, constitutive Notch signaling. The oncogenic mechanism involves sustained expression of MYC and other proliferation-associated genes. γ-secretase inhibitors have been tested in clinical trials for T-ALL, though their efficacy has been limited by on-target gastrointestinal toxicity. For a comprehensive review, see Notch Signaling in Cancer.

Notch signaling also plays roles in other malignancies. In breast cancer, NOTCH1 and NOTCH4 are frequently overexpressed, and Notch signaling promotes cancer stem cell self-renewal. In colorectal cancer, Notch signaling cooperates with Wnt signaling to drive tumorigenesis. However, Notch can also act as a tumor suppressor in some contexts, such as in skin and small cell lung cancer, where loss-of-function mutations are found.

Loss-of-Function Disorders

Loss-of-function mutations in Notch pathway components cause developmental disorders:

Alagille syndrome: Caused by mutations in JAG1 (in ~90% of cases) or NOTCH2 (in ~1%). This autosomal dominant disorder affects the liver (bile duct paucity), heart (pulmonary stenosis), eyes (posterior embryotoxon), and skeleton (butterfly vertebrae). The mechanism involves haploinsufficiency—reduced gene dosage of the ligand or receptor disrupts bile duct development.

CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy): Caused by mutations in NOTCH3. The mutations cluster in the EGF repeats and lead to accumulation of the Notch3 extracellular domain in cerebral blood vessels, causing progressive vascular dementia and stroke.

Spondylocostal dysostosis: Caused by mutations in DLL3, LFNG, or MESP2, all components of the Notch pathway involved in somitogenesis. Affected individuals have severe vertebral and rib malformations.

Hajdu-Cheney syndrome: Caused by mutations in NOTCH2 that truncate the PEST domain, leading to enhanced signaling. This disorder is characterized by severe osteoporosis and acro-osteolysis.

Experimental Methods to Study Notch Delta Signaling

Studying Notch Delta signaling requires methods that respect its juxtacrine nature. Many standard techniques for studying secreted signaling pathways are inappropriate or require modification.

Cell-Based Assays

The most common cell-based assay is the co-culture assay. A "signal-sending" cell line expressing Delta (e.g., NIH3T3 cells stably transfected with DLL1) is co-cultured with a "signal-receiving" cell line expressing Notch (e.g., U2OS or HEK293 cells). The readout can be:

Reporter assays: The receiving cells carry a luciferase reporter driven by a promoter containing CSL-binding sites (CBF1-luciferase). After 24–48 hours of co-culture, cells are lysed and luciferase activity is measured. A typical assay uses 10,000–50,000 receiving cells per well of a 96-well plate, co-cultured with an equal number of sending cells. The reporter plasmid (e.g., 4xCSL-luciferase) is transfected at 100–200 ng per well along with a Renilla luciferase control (10 ng per well) for normalization.

Western blotting for NICD: Receiving cells are lysed, and proteins are separated by SDS-PAGE. NICD is detected using an antibody specific for the cleaved intracellular domain (e.g., cleaved NOTCH1 antibody, which recognizes the Val1744 cleavage site). A typical protocol uses 20–40 μg of total protein per lane, transferred to PVDF membrane, and probed with the antibody at 1:1000 dilution in 5% BSA-TBST overnight at 4°C.

Quantitative RT-PCR: Expression of Notch target genes (HES1, HEY1, MYC) is measured by qRT-PCR. RNA is extracted using Trizol, and cDNA is synthesized using random hexamers. SYBR Green-based qPCR is performed with 40 cycles of amplification (95°C for 15 s, 60°C for 60 s).

A critical control is the use of γ-secretase inhibitor (e.g., DAPT at 10 μM) to confirm that the observed response is Notch-dependent. DAPT treatment should abolish NICD production and target gene expression.

Imaging and Microscopy

Fluorescence microscopy is used to visualize Notch pathway components. Common approaches include:

Immunofluorescence: Cells are fixed in 4% paraformaldehyde for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100, and blocked in 5% normal goat serum. Primary antibodies against Notch1 (1:200) and NICD (1:100) are incubated overnight at 4°C, followed by fluorescent secondary antibodies (1:500) for 1 hour at room temperature.

Live-cell imaging: To observe ligand-induced receptor conformational changes, FRET (Förster resonance energy transfer) or bioluminescence resonance energy transfer (BRET) can be used. Notch is tagged with a donor fluorophore and the NRR with an acceptor; ligand binding causes a conformational change that alters FRET efficiency.

Tissue sections: In developmental studies, whole-mount in situ hybridization or immunohistochemistry on tissue sections (10–20 μm thick) is used to visualize Delta and Notch expression patterns.

Genetic Manipulation

RNA interference (RNAi): siRNA or shRNA targeting NOTCH1, DLL1, or downstream effectors can be used to knock down gene expression. A typical siRNA transfection uses 25–50 nM siRNA with Lipofectamine RNAiMAX, with knockdown assessed at 48–72 hours post-transfection.

CRISPR/Cas9: Gene knockout is achieved by transfecting cells with Cas9 and a guide RNA targeting the gene of interest. For NOTCH1, a guide RNA targeting exon 2 (encoding the signal peptide) is commonly used. Knockout efficiency is verified by Western blotting for full-length Notch1.

Dominant-negative constructs: A dominant-negative Mastermind-like (dnMAML) construct, which lacks the transactivation domain, can be expressed to block Notch transcriptional activity. This is a useful tool to distinguish canonical (CSL-dependent) from non-canonical Notch signaling.

Conditional knockout mice: The Notch1 floxed allele combined with tissue-specific Cre drivers allows temporal and spatial control of Notch deletion. For example, Nestin-Cre; Notch1^fl/fl mice lack Notch1 in neural progenitors.

Common Pitfalls and Misconceptions

Students frequently encounter several conceptual and technical difficulties when studying Notch Delta signaling. Understanding these pitfalls is essential for accurate interpretation of experimental data.

Notch is not a secreted factor

A common misconception is that Notch signaling involves a secreted ligand diffusing to a distant receptor. This is incorrect. Both Notch and Delta are transmembrane proteins, and signaling requires direct cell–cell contact. This is why conditioned medium from Delta-expressing cells cannot activate Notch on receiving cells. If you are designing an experiment, you must co-culture the cells physically. Transwell assays, where sending and receiving cells are separated by a porous membrane, will not produce signaling unless the pore size allows cell contact.

Ligand and receptor are both membrane-bound

Related to the above, students sometimes assume that the ligand is secreted and the receptor is membrane-bound, as in receptor tyrosine kinase signaling. In Notch signaling, both the ligand and the receptor are membrane-tethered. This has an important consequence: the signal-sending cell must express the ligand on its surface, and the signal-receiving cell must express the receptor on its surface. A cell cannot send and receive Notch signals simultaneously to the same neighbor in a simple reciprocal manner without additional regulation.

Cleavage order matters

The proteolytic cleavages must occur in a strict order: S1 (furin, in the Golgi, during maturation), S2 (ADAM, at the plasma membrane, after ligand binding), and S3 (γ-secretase, in the membrane, after S2). A frequent error is to assume that γ-secretase can cleave full-length Notch directly. It cannot—the S2 cleavage is a prerequisite. This is why ADAM inhibitors (e.g., TAPI-1) block Notch signaling as effectively as γ-secretase inhibitors. When interpreting Western blots, you should expect to see the full-length Notch (~300 kDa), the S2-cleaved NEXT fragment (~120 kDa), and NICD (~110 kDa) only after ligand stimulation.

γ-secretase inhibitors are not specific to Notch

γ-Secretase cleaves many substrates besides Notch, including the amyloid precursor protein (APP), CD44, and ErbB4. Therefore, treatment with DAPT or Compound E does not specifically inhibit Notch signaling. If you observe a phenotype with a γ-secretase inhibitor, you must confirm Notch specificity using genetic approaches (e.g., Notch knockdown or dnMAML expression).

NICD detection requires the right antibody

Many commercial Notch antibodies recognize the full-length receptor but not NICD. To detect NICD specifically, you must use an antibody that recognizes the neo-epitope generated by γ-secretase cleavage (e.g., cleaved NOTCH1 Val1744). Using a pan-Notch1 antibody will not distinguish between full-length and cleaved forms.

Reporter assays require appropriate controls

CBF1-luciferase reporters are sensitive but can produce false positives. Always include a negative control where the CSL-binding sites are mutated, and a positive control where NICD is overexpressed. Additionally, some cell lines have high endogenous CSL activity, which can mask ligand-induced activation. The choice of cell line matters: U2OS and HeLa cells are commonly used because they have low basal Notch activity.

Summary and Key Takeaways

Notch Delta signaling is a direct, contact-dependent signaling pathway that controls cell fate decisions throughout development and adult life. The pathway operates through a series of proteolytic cleavages that release the Notch intracellular domain, which then acts as a transcriptional co-activator. The pathway is regulated at multiple levels, including glycosylation, endocytosis, and ubiquitination, and its dysregulation contributes to cancer and developmental disorders.

Frequently Asked Questions

What is Notch Delta signaling?

Notch Delta signaling is a juxtacrine cell–cell communication pathway in which a Delta ligand on one cell binds to a Notch receptor on an adjacent cell. This binding triggers a proteolytic cascade that releases the Notch intracellular domain (NICD), which translocates to the nucleus and regulates gene expression. The pathway controls cell fate decisions such as differentiation, proliferation, and apoptosis.

How does Notch Delta signaling work?

The process involves five steps: (1) Delta ligand on the signal-sending cell binds to Notch receptor on the signal-receiving cell; (2) ligand binding induces a conformational change in the Notch negative regulatory region, exposing the S2 cleavage site; (3) ADAM metalloprotease cleaves at S2, releasing the extracellular domain; (4) γ-secretase cleaves at S3 within the transmembrane domain, releasing NICD; (5) NICD translocates to the nucleus, binds CSL, and activates transcription of target genes such as HES1 and MYC.

What is the difference between Notch and Delta?

Notch is the receptor, and Delta is the ligand. Notch is a large single-pass transmembrane protein with EGF-like repeats in its extracellular domain and a transcriptional activation domain in its intracellular region. Delta is also a transmembrane protein, but it is smaller and contains a DSL domain that mediates binding to Notch. The signal-sending cell expresses Delta; the signal-receiving cell expresses Notch.

Why is Notch signaling called juxtacrine?

Juxtacrine signaling means that the signal requires direct physical contact between the signaling and receiving cells. Unlike paracrine signaling, where a secreted ligand diffuses through the extracellular space, Notch ligands are membrane-bound and cannot diffuse. The term "juxtacrine" comes from the Latin juxta (next to) and refers to signaling between adjacent cells.

What are the main components of Notch Delta signaling?

The main components are: (1) the Notch receptor (NOTCH1–4 in mammals); (2) the Delta ligands (DLL1, DLL3, DLL4) and Jagged ligands (JAG1, JAG2); (3) the proteases ADAM10/17 and γ-secretase; (4) the transcription factor CSL (CBF1/RBP-Jκ); (5) the co-activator Mastermind-like (MAML); and (6) downstream target genes including the HES and HEY families.

What happens when Notch signaling is dysregulated?

Dysregulation can cause cancer or developmental disorders. Activating mutations in NOTCH1 are found in ~50% of T-ALL cases, leading to constitutive signaling and uncontrolled proliferation. Loss-of-function mutations cause Alagille syndrome (JAG1, NOTCH2), CADASIL (NOTCH3), and spondylocostal dysostosis (DLL3, LFNG). The outcome depends on whether signaling is increased or decreased and on the tissue context.

How is Notch Delta signaling studied experimentally?

Common methods include: co-culture assays with Delta-expressing and Notch-expressing cells; reporter assays using CBF1-luciferase plasmids; Western blotting for cleaved NICD; quantitative RT-PCR for target genes; immunofluorescence microscopy; RNAi or CRISPR-mediated knockdown/knockout; and γ-secretase inhibitor treatment (with appropriate specificity controls).

Key Takeaways

Notch Delta signaling is juxtacrine: it requires direct cell–cell contact because both ligand and receptor are membrane-bound.
Signal transduction is mediated by regulated proteolysis: S2 cleavage by ADAM, then S3 cleavage by γ-secretase, releasing NICD.
NICD acts as a transcriptional co-activator in the nucleus, binding CSL and recruiting MAML to activate target genes.
The pathway is regulated by Fringe glycosylation, endocytic trafficking, and ubiquitin-mediated degradation of NICD.
Notch Delta signaling controls lateral inhibition, boundary formation, and stem cell maintenance during development.
Dysregulation causes T-ALL (activating mutations), Alagille syndrome (loss-of-function), and CADASIL (NOTCH3 mutations).
Experimental study requires co-culture assays, NICD-specific antibodies, and careful controls for γ-secretase inhibitor specificity.